Dickson G - Search Results

1

RAC1B modulates intestinal tumourigenesis via modulation of WNT and EGFR signalling pathways.

Gudiño V, Pohl SÖ, Billard CV, Cammareri P, Bolado A, Aitken S, Stevenson D, Hall AE, Agostino M, Cassidy J, Nixon C, von Kriegsheim A, Freile P, Popplewell L, Dickson G, Murphy L, Wheeler A, Dunlop M, Din F, Strathdee D, Sansom OJ, Myant KB. Gudiño V, et al. Among authors: dickson g. Nat Commun. 2021 Apr 20;12(1):2335. doi: 10.1038/s41467-021-22531-3. Nat Commun. 2021. PMID: 33879799 Free PMC article.

2

Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.

Popplewell LJ, Malerba A, Dickson G. Popplewell LJ, et al. Among authors: dickson g. Methods Mol Biol. 2012;867:143-67. doi: 10.1007/978-1-61779-767-5_10. Methods Mol Biol. 2012. PMID: 22454060

3

Genetic therapeutic approaches for Duchenne muscular dystrophy.

Foster H, Popplewell L, Dickson G. Foster H, et al. Among authors: dickson g. Hum Gene Ther. 2012 Jul;23(7):676-87. doi: 10.1089/hum.2012.099. Hum Gene Ther. 2012. PMID: 22647146 Review.

4

Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice.

Koo T, Popplewell L, Athanasopoulos T, Dickson G. Koo T, et al. Among authors: dickson g. Hum Gene Ther. 2014 Feb;25(2):98-108. doi: 10.1089/hum.2013.164. Epub 2013 Dec 19. Hum Gene Ther. 2014. PMID: 24191945

5

Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.

Lu-Nguyen N, Malerba A, Herath S, Dickson G, Popplewell L. Lu-Nguyen N, et al. Among authors: dickson g. Hum Mol Genet. 2021 Jul 9;30(15):1398-1412. doi: 10.1093/hmg/ddab136. Hum Mol Genet. 2021. PMID: 33987655 Free PMC article.

6

Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit DUX4 Expression.

Lu-Nguyen N, Dickson G, Malerba A, Popplewell L. Lu-Nguyen N, et al. Among authors: dickson g. Biomedicines. 2022 Jul 7;10(7):1623. doi: 10.3390/biomedicines10071623. Biomedicines. 2022. PMID: 35884928 Free PMC article.

7

Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene.

Popplewell LJ, Trollet C, Dickson G, Graham IR. Popplewell LJ, et al. Among authors: dickson g. Mol Ther. 2009 Mar;17(3):554-61. doi: 10.1038/mt.2008.287. Epub 2009 Jan 13. Mol Ther. 2009. PMID: 19142179 Free PMC article.

8

Gene therapy for muscular dystrophy: current progress and future prospects.

Trollet C, Athanasopoulos T, Popplewell L, Malerba A, Dickson G. Trollet C, et al. Among authors: dickson g. Expert Opin Biol Ther. 2009 Jul;9(7):849-66. doi: 10.1517/14712590903029164. Expert Opin Biol Ther. 2009. PMID: 19527108 Review.

9

Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment.

Kang JK, Malerba A, Popplewell L, Foster K, Dickson G. Kang JK, et al. Among authors: dickson g. Mol Ther. 2011 Jan;19(1):159-64. doi: 10.1038/mt.2010.212. Epub 2010 Oct 5. Mol Ther. 2011. PMID: 20924365 Free PMC article.

10

Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.

Popplewell LJ, Graham IR, Malerba A, Dickson G. Popplewell LJ, et al. Among authors: dickson g. Methods Mol Biol. 2011;709:153-78. doi: 10.1007/978-1-61737-982-6_10. Methods Mol Biol. 2011. PMID: 21194027

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

449 results

Search Page

Filters